Stockscreener 앱 받기
0.67
3.67%
-0.0255
시간 외 거래:
.68
0.01
+1.49%
전일 마감가:
$0.6955
열려 있는:
$0.703
하루 거래량:
7.05M
Relative Volume:
0.86
시가총액:
$185.66M
수익:
$232.40M
순이익/손실:
$-20.51M
주가수익비율:
-8.69
EPS:
-0.0771
순현금흐름:
$60.04M
1주 성능:
-16.36%
1개월 성능:
-27.00%
6개월 성능:
-50.37%
1년 성능:
-77.05%
1일 변동 폭
$0.6659
$0.7337
1주일 범위
$0.6659
$0.8069
52주 변동 폭
$0.6659
$3.20
Akebia Therapeutics Inc Stock (AKBA) Company Profile
명칭
Akebia Therapeutics Inc
전화
617-871-2098
주소
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
0.67 | 185.66M | 232.40M | -20.51M | 60.04M | -0.0771 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-08-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-06-04 | 재개 | H.C. Wainwright | Buy |
| 2025-04-28 | 개시 | Leerink Partners | Outperform |
| 2025-04-01 | 개시 | Jefferies | Buy |
| 2023-11-29 | 재개 | BTIG Research | Buy |
| 2023-08-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Needham | Buy → Hold |
| 2022-03-31 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-14 | 재확인 | Needham | Buy |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-11 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-02 | 개시 | JP Morgan | Overweight |
| 2019-03-20 | 개시 | Citigroup | Neutral |
| 2018-09-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2018-08-10 | 재확인 | Needham | Buy |
| 2018-06-06 | 재확인 | H.C. Wainwright | Buy |
| 2017-12-19 | 개시 | Piper Jaffray | Overweight |
| 2017-12-07 | 개시 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | Needham | Buy |
| 2016-12-27 | 재확인 | H.C. Wainwright | Buy |
| 2016-12-20 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-15 | 개시 | Aegis Capital | Buy |
| 2016-09-29 | 개시 | Brean Capital | Buy |
| 2016-03-16 | 재확인 | Needham | Buy |
| 2016-01-21 | 개시 | Credit Suisse | Neutral |
모두보기
Akebia Therapeutics Inc 주식(AKBA)의 최신 뉴스
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Has Average Target Price of $3.90 - MarketBeat
Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026 - Yahoo Finance
Akebia Therapeutics, Inc. (AKBA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
A new hire's right to buy 8,400 Akebia shares phases in over four years, if they stay. - Stock Titan
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Long term debt to total equity ratio of Akebia Therapeutics, Inc. – HAN:AX9 - tradingview.com
Akebia Therapeutics, Inc. Revenue Breakdown – MUN:AX9 - TradingView
Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights - Lelezard
Akebia Therapeutics, Inc. $AKBA Position Reduced by State Street Corp - MarketBeat
AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits
Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Exploring A 337% Potential Upside - DirectorsTalk Interviews
Akebia Therapeutics Doses First Patient in Phase 2 Ebribafusp Trial - marketscreener.com
One trial, three rare kidney diseases: Akebia doses its first patient - Stock Titan
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases - Yahoo Finance
Akebia Therapeutics Announces First Patient Dosed in Phase - globenewswire.com
Akebia Therapeutics Announces First Patient Dosed in Phase - GlobeNewswire
Akebia Therapeutics (NasdaqCM:AKBA) Stock Forecast & Analyst Predictions - simplywall.st
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Upgraded by Wall Street Zen to Hold Rating - marketbeat.com
AKBA Initiates Coverage On WestPark Capital -- Rating Set to Buy - GuruFocus
Akebia Therapeutics (NASDAQ:AKBA) Earns Buy Rating from Analysts at Westpark Capital - marketbeat.com
BlackRock Inc. Buys Shares of 19,986,374 Akebia Therapeutics, Inc. $AKBA - marketbeat.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston - marketscreener.com
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston - GlobeNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston - Yahoo Finance
Nantahala Capital Management LLC Takes Position in Akebia Therapeutics, Inc. $AKBA - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Stock Price Passes Below 200-Day Moving AverageWhat's Next? - MarketBeat
Akebia (AKBA) Market: Slides 1.39% to $0.91 for the Current Session; Key Range: the Near-Term Reference Band Stretches From $0.86 to $0.96 on the DayRTH Profile - vinanet.vn
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Rating of "Hold" by Analysts - MarketBeat
Akebia Therapeutics, Inc. Revenue Breakdown – NASDAQ:AKBA - TradingView
Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
AKBA Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates by 33.18%Return On Equity - vinanet.vn
Akebia Therapeutics CEO John P. Butler Exercises 350,000 Stock Options at $0.63 Each - Kalkine Media
Weekly Recap: Vafseo sales surge and ebribafusp Phase 2 trial start - TradingView
Akebia Therapeutics, Inc. $AKBA Shares Sold by Renaissance Technologies LLC - MarketBeat
HC Wainwright Has Negative Outlook of AKBA FY2026 Earnings - MarketBeat
Akebia Therapeutics (AKBA) AGM 2026 Summary - Quartr
Akebia Therapeutics Price Target Announced at $1.00/Share by Leerink Partners - Moomoo
Akebia Therapeutics Inc (AKBA) Stock News Today - TradingKey
Akebia Therapeutics Inc (AKBA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Leerink Partners to "Market Perform" - MarketBeat
Akebia Therapeutics Inc (AKBA:UR): Stock Price, Quote and News - BNN Bloomberg
Akebia Therapeutics, Inc. (AKBA) Investor Outlook: Analyzing a 340% Potential Upside Amid Healthcare Innovation - DirectorsTalk Interviews
AKBA Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers 55.5% EPS SurpriseEarnings Season Outlook - vinanet.vn
H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Akebia Therapeutics Inc (AKBA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Akebia Therapeutics Inc 주식 (AKBA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ostrowski Erik | SVP, CFO, CBO & Treasurer |
Jun 29 '26 |
Sale |
1.11 |
56,019 |
62,181 |
616,616 |
| Ostrowski Erik | Officer |
Jun 29 '26 |
Proposed Sale |
1.11 |
56,019 |
62,220 |
0 |
| Butler John P. | CEO and President |
Mar 04 '26 |
Buy |
1.25 |
69,270 |
86,588 |
3,367,064 |
| Malabre Richard C | SVP, Chief Accounting Officer |
Feb 02 '26 |
Sale |
1.39 |
49,524 |
68,838 |
299,390 |
| Grund Nicholas | Chief Commercial Officer |
Feb 02 '26 |
Sale |
1.39 |
84,829 |
117,912 |
561,750 |
| Burke Steven Keith | SVP, Chief Medical Officer |
Feb 02 '26 |
Sale |
1.39 |
67,658 |
94,045 |
948,432 |
| Rucci Carolyn M. | SVP, Chief Legal Officer |
Feb 02 '26 |
Sale |
1.39 |
69,772 |
96,983 |
588,378 |
| Ostrowski Erik | SVP, CFO, CBO & Treasurer |
Feb 02 '26 |
Sale |
1.39 |
34,951 |
48,582 |
672,635 |
| Butler John P. | CEO and President |
Feb 02 '26 |
Sale |
1.39 |
341,305 |
474,414 |
3,206,233 |
| Ostrowski Erik | Officer |
Feb 02 '26 |
Proposed Sale |
1.39 |
34,951 |
48,739 |
0 |
6.04%
자본화:
|
볼륨(24시간):